DexCom Q4 2021 Earnings Report
Key Takeaways
DexCom reported a 23% increase in worldwide revenue for Q4 2021, reaching $698.2 million. However, GAAP operating income decreased significantly, and the company experienced a GAAP net loss of $19.4 million, or $0.20 per diluted share.
Revenue grew 23% to $698.2 million compared to the same quarter of the prior year.
U.S. revenue grew 15% and international revenue grew 54%.
GAAP operating income was $0.6 million, a decrease of 1,820 basis points compared to Q4 2020.
GAAP net loss was $19.4 million, or $0.20 per diluted share, compared to GAAP net income of $355.2 million in Q4 2020.
DexCom
DexCom
DexCom Revenue by Segment
DexCom Revenue by Geographic Location
Forward Guidance
The company is reiterating guidance for fiscal year 2022 revenue, and establishing guidance for full year Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin to the following levels:
Positive Outlook
- Revenue of approximately $2.82 - 2.94 billion (15-20% growth)
- Non-GAAP Gross Profit Margin of approximately 65%
- Non-GAAP Operating Margin of approximately 16%
- Adjusted EBITDA Margin of approximately 25%
Revenue & Expenses
Visualization of income flow from segment revenue to net income